83 FR 61658 - National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 231 (November 30, 2018)

Page Range		61658-61658
FR Document		2018-26017

Federal Register, Volume 83 Issue 231 (Friday, November 30, 2018)

[Federal Register Volume 83, Number 231 (Friday, November 30, 2018)]
[Notices]
[Page 61658]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-26017]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; Contract Review.
    Date: December 14, 2018.
    Time: 12:00 p.m. to 6:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference 
Call).
    Contact Person: Michele L. Barnard, Ph.D., Scientific Review 
Officer, Review Branch, DEA, NIDDK, National Institutes of Health, 
Room 7353, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301) 
594-8898, [email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and funding 
cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: November 21, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-26017 Filed 11-29-18; 8:45 am]
 BILLING CODE 4140-01-P

61658 Federal Register / Vol. 83, No. 231 / Friday, November 30, 2018 / Notices

audio teleconference. Space is limited Agenda: To evaluate the NCI Experimental Place: National Institutes of Health, Two
and registration is preferred in order to Therapeutics Program Portfolio. Democracy Plaza, 6707 Democracy
attend in-person or by phone. Place: National Institutes of Health, 9000 Boulevard, Bethesda, MD 20892, (Telephone
Rockville Pike, Building 1, Wilson Hall, Conference Call).
Registration may be completed online at Bethesda, MD 20892. Contact Person: Michele L. Barnard, Ph.D.,
http://www.cvent.com/d/gbq2tg. Contact Persons: Barbara Mroczkowski, Scientific Review Officer, Review Branch,
The following information is Ph.D., Executive Secretary, Discovery DEA, NIDDK, National Institutes of Health,
submitted when registering: Experimental Therapeutics Program, Room 7353, 6707 Democracy Boulevard,
Name: National Cancer Institute, NIH 31 Center Bethesda, MD 20892–2542, (301) 594–8898,
Company/organization name: Drive, Room 3A44, Bethesda, MD 20817, barnardm@extra.niddk.nih.gov.
Postal address: (301) 496–4291, mroczkoskib@mail.nih.gov.
Toby Hecht, Ph.D., Executive Secretary, This notice is being published less
Email address:
Persons wishing to attend a PTAC Development Experimental Therapeutics than 15 days prior to the meeting due
meeting must register by following the Program, National Cancer Institute, NIH, to the timing limitations imposed by the
9609 Medical Center Drive, Room 3W110, review and funding cycle.
instructions in the ‘‘Meeting Rockville, MD 20850, (240) 276–5683,
Registration’’ section of this notice. A toby.hecht2@nih.gov. (Catalogue of Federal Domestic Assistance
confirmation email will be sent to Program Nos. 93.847, Diabetes,
This notice is being published less than 15 Endocrinology and Metabolic Research;
registrants shortly after completing the days prior to the meeting due to the timing 93.848, Digestive Diseases and Nutrition
registration process. limitations imposed by the review and
Research; 93.849, Kidney Diseases, Urology
Dated: November 14, 2018. funding cycle.
and Hematology Research, National Institutes
Brenda Destro, (Catalogue of Federal Domestic Assistance of Health, HHS)
Program Nos. 93.392, Cancer Construction;
Deputy Assistant Secretary for Planning and 93.393, Cancer Cause and Prevention Dated: November 21, 2018.
Evaluation (HSP). Research; 93.394, Cancer Detection and Melanie J. Pantoja,
[FR Doc. 2018–25992 Filed 11–29–18; 8:45 am] Diagnosis Research; 93.395, Cancer Program Analyst, Office of Federal Advisory
BILLING CODE 4150–15–P Treatment Research; 93.396, Cancer Biology Committee Policy.
Research; 93.397, Cancer Centers Support;
[FR Doc. 2018–26017 Filed 11–29–18; 8:45 am]
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health, BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HHS)
HUMAN SERVICES
Dated: November 26, 2018. DEPARTMENT OF HEALTH AND
National Institutes of Health
Melanie J. Pantoja, HUMAN SERVICES
National Cancer Institute; Notice of Program Analyst, Office of Federal Advisory
Committee Policy. National Institutes of Health
Closed Meeting
[FR Doc. 2018–26015 Filed 11–29–18; 8:45 am]
Pursuant to section 10(d) of the National Institute of Allergy and
BILLING CODE 4140–01–P
Federal Advisory Committee Act, as Infectious Diseases; Notice of Closed
amended, notice is hereby given of the Meeting
following meeting. DEPARTMENT OF HEALTH AND Pursuant to section 10(d) of the
The meeting will be closed to the HUMAN SERVICES Federal Advisory Committee Act, as
public in accordance with the
amended (5 U.S.C. App.), notice is
provisions set forth in sections National Institutes of Health hereby given of a meeting of the Vaccine
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
National Institute of Diabetes and Research Center Board of Scientific
as amended. The purpose of this
Digestive and Kidney Diseases; Notice Counselors, NIAID.
meeting is to evaluate requests for
preclinical development resources for of Closed Meeting The meeting will be closed to the
potential new therapeutics for the public as indicated below in accordance
Pursuant to section 10(d) of the with the provisions set forth in section
treatment of cancer. The outcome of the Federal Advisory Committee Act, as
evaluation will provide information to 552b(c)(6), Title 5 U.S.C., as amended
amended, notice is hereby given of the for the review, discussion, and
internal NCI committees that will following meeting.
decide whether NCI should support evaluation of individual intramural
The meeting will be closed to the programs and projects conducted by the
requests and make available contract public in accordance with the
resources for development of the National Institute Of Allergy And
provisions set forth in sections Infectious Diseases, including
potential therapeutic to improve the 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
treatment of various forms of cancer. consideration of personnel
as amended. The contract proposals and qualifications and performance, and the
The research proposals and the the discussions could disclose
discussions could disclose confidential competence of individual investigators,
confidential trade secrets or commercial the disclosure of which would
trade secrets or commercial property property such as patentable material,
such as patentable material, and constitute a clearly unwarranted
and personal information concerning invasion of personal privacy.
personal information concerning individuals associated with the contract
individuals associated with the proposals, the disclosure of which Name of Committee: Vaccine Research
proposed research projects, the Center Board of Scientific Counselors, NIAID.
would constitute a clearly unwarranted Date: December 12–13, 2018.
disclosure of which would constitute a
amozie on DSK3GDR082PROD with NOTICES1

invasion of personal privacy. Time: 8:00 a.m. to 5:00 p.m.
clearly unwarranted invasion of
Name of Committee: National Institute of Agenda: To review and evaluate personal
personal privacy. qualifications and performance, and
Diabetes and Digestive and Kidney Diseases
Name of Committee: National Cancer Special Emphasis Panel; Contract Review. competence of individual investigators.
Institute Special Emphasis Panel, OCT2018 Date: December 14, 2018. Place: National Institutes of Health, 40
Cycle 30 NExT SEP Committee Meeting. Time: 12:00 p.m. to 6:00 p.m. Convent Drive, Bethesda, MD 20892.
Date: December 12, 2018. Agenda: To review and evaluate contract Contact Person: John R Mascola, MD,
Time: 9:00 a.m. to 3:00 p.m. proposals. Deputy Director, Vaccine Research Center,

VerDate Sep<11>2014 17:00 Nov 29, 2018 Jkt 247001 PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 E:\FR\FM\30NON1.SGM 30NON1

Document Created: 2018-11-30 04:35:45
Document Modified: 2018-11-30 04:35:45

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		December 14, 2018.
FR Citation		83 FR 61658

83 FR 61658 - National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 231 (November 30, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health